Published: 13 November 2020
Author(s): Cheng-Han Lee, Hui-Wen Lin, Nan-Yao Lee, Sheng-Hsiang Lin, Yi-Heng Li
Issue: April 2021
Section: Letter to the Editor

Ticagrelor is an oral direct-acting antiplatelet agent that inhibits P2Y12 receptor activation. The PLATO study showed that ticagrelor significantly reduced the composite outcome of vascular death, myocardial infarction (MI) or stroke compared to clopidogrel in patients with acute coronary syndrome (ACS) [1]. Post hoc analysis of the PLATO study demonstrated a lower mortality rate of pneumonia and sepsis in the ticagrelor group [2]. Moreover, a recent study found that ticagrelor possessed direct bactericidal activity against gram positive cocci (GPC) [3].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.